Did UnitedHealth Game the System? How Risk Adjustment Became a $500 Billion Medicare Advantage Machine

IMC Board
Jan 14
7 min read

When does smart business strategy cross the line?

That's the question now facing the entire insurance industry after a January 12, 2026 bombshell Senate Judiciary Committee report detailed how UnitedHealth Group transformed Medicare Advantage risk adjustment from a payment mechanism into what U.S. Senator Chuck Grassley called "its own business."

Key Takeaways:

Senate investigation reveals systematic approach—UnitedHealth uses AI-powered data mining, in-home visits, and specialized coding teams to maximize Medicare Advantage diagnoses and federal reimbursements
Industry-wide implications—UnitedHealth sells its diagnosis capture systems to other insurers, potentially reshaping the entire Medicare Advantage market
Regulatory scrutiny intensifies—The company faces concurrent DOJ criminal investigations while navigating new CMS risk adjustment models
Operational blueprint exposed—50K+ pages of internal documents reveal specific tactics including targeted screening protocols, provider incentives, and rapid adaptation to regulatory changes
Financial pressure mounting—UnitedHealth cut 2025 earnings guidance and faces market volatility as Medicare Advantage represents 40% of total revenues
Competitive intelligence goldmine—Understanding these strategies provides critical insights for carriers, agents positioning Medicare Advantage products, and marketers targeting senior health care audiences

Medicare Advantage was designed with a straightforward incentive: pay insurers more for sicker patients so they wouldn't cherry-pick only healthy enrollees. The risk adjustment formula seemed simple: document more chronic conditions, then receive higher monthly payments from the federal government.

But what happens when an insurer builds an entire business model around finding and documenting those diagnoses? When data mining, artificial intelligence, and vertically integrated provider networks converge to systematically maximize every possible diagnosis code?

The investigation, based on over 50,000 pages of internal UnitedHealth documents, exposes an operation that leveraged artificial intelligence (AI), vertically integrated provider networks, and specialized coding teams to capture diagnoses at a scale no competitor could match.

For insurance carriers, agents, and digital marketers, this isn't just a compliance story. It's a masterclass in data-driven health care strategy and a warning about the regulatory reckoning ahead.

Mechanics of a $500 Billion Machine

Medicare Advantage has become the crown jewel of health insurance, with the program paying nearly half a trillion dollars to private insurers in 2024 to cover approximately 50% of Medicare beneficiaries. For UnitedHealth, it represents 40% of total consolidated revenues, making it the company's single largest revenue source.

The Senate report reveals how UnitedHealth built a diagnosis capture infrastructure unmatched in the industry. According to the investigation, the company deployed multiple interconnected systems to identify and document conditions that drive higher risk-adjusted payments from the U.S. Centers for Medicare and Medicaid Services (CMS).

Four Pillars of Diagnosis Optimization

The Senate investigation identified four interconnected systems that work together to maximize diagnosis capture. Understanding these mechanisms provides valuable competitive intelligence for carriers looking to optimize their own risk adjustment operations while staying within regulatory boundaries. Each pillar reinforces the others, creating a flywheel effect that becomes more powerful as data accumulates and processes refine.

1. Data Mining at Industrial Scale

UnitedHealth analyzes enrollee claims data including prescription medications, specialist visits, and urgent care encounters to identify patients likely to have undocumented conditions. This intelligence feeds directly into the company's outreach programs, creating a closed-loop system in which data predicts gaps and operations fill them.

2. The HouseCalls Program

Optum, UnitedHealth's health services subsidiary, deployed nurse practitioners to conduct 2.9 million free in-home visits to Medicare Advantage enrollees in 2024 alone. While UnitedHealth describes these as preventive care to help seniors "live healthier at home," the Senate report characterizes them as a diagnosis capture mechanism designed to drive risk scores higher.

The investigation found that these visits included targeted screenings for specific conditions including peripheral artery disease using point-of-care technologies like the QuantaFlo device. However, UnitedHealth reportedly stopped using this device after Medicare rule adjustments affected its profitability.

3. Systematic Chart Reviews

Medical coders employed or contracted by UnitedHealth conduct secondary reviews of external medical records specifically to identify documented conditions not listed on invoices. This practice finds diagnoses that treating physicians may have noted, but didn't formally code for billing purposes.

4. Vertically Integrated Provider Control

OptumHealth, the care delivery arm of UnitedHealth's Optum subsidiary, employs or contracts with tens of thousands of physicians who treat UnitedHealthcare Medicare Advantage members. This vertical integration creates what the Senate called "closed-loop control" where UnitedHealth can directly influence provider documentation and coding practices.

Rapid Adaptation Advantage

Perhaps most striking is UnitedHealth's ability to pivot when CMS attempts to crack down on coding intensity. The Senate investigation documented how the company uses its data assets and AI capabilities to continuously identify new diagnosis capture opportunities.

When CMS removes or downgrades certain diagnosis codes, UnitedHealth quickly identifies alternative pathways. The report highlighted examples in opioid dependence, alcohol use disorder, and dementia when the company developed proprietary diagnostic criteria that may not align with standard medical guidelines.

For instance, UnitedHealth guidance reportedly tells providers to diagnose "physical dependence" of opioids in patients who take prescribed medications as directed and would experience withdrawal from abrupt cessation even if they've never actually experienced withdrawal symptoms. This allows capturing certain opioid dependence codes typically associated with moderate to severe use disorder.

B2B Revenue Stream

UnitedHealth doesn't just use these systems internally. The company sells its diagnosis capture insights, coding guidelines, and even workforce services to other Medicare Advantage organizations. This creates what the Senate report called "new 'standard' definitions for diagnoses and diagnosis codes within the MA space."

For competing carriers, this represents both an opportunity and a challenge. Partnering with UnitedHealth's systems may improve risk adjustment performance but also deepens dependence on a direct competitor's infrastructure.

Legal and Regulatory Crossfire

The Senate report arrives amid mounting legal pressure. The Department of Justice opened a criminal investigation into UnitedHealth's Medicare billing practices, with prosecutors questioning doctors about the company's coding activities. The company also faces an ongoing False Claims Act whistleblower lawsuit filed in 2011 by a former UnitedHealth finance director.

UnitedHealth asserts that its programs "comply with applicable CMS requirements and have, through government audits, demonstrated sustained adherence to regulatory standards." The company emphasizes that Medicare Advantage costs taxpayers less than traditional fee-for-service Medicare while delivering more value to seniors.

However, the U.S. Department of Justice (DOJ) previously secured a $172 million settlement with Cigna over similar allegations, establishing precedent for enforcement actions in this space.

Market Impact and Industry Implications

UnitedHealth's stock dropped as much as 2.9% following the report's release. The company has already cut its 2025 earnings guidance to $26-$26.50 per share, citing health care activity that increased at twice the expected rate in Medicare Advantage and challenges transitioning to a new CMS risk model.

The broader market responded negatively as well, with Humana down 1.04%, CVS Health down 1.45%, Elevance Health down 1.14%, and Centene down 2.44%. The Senate noted that while its investigation focused on UnitedHealth, all Medicare Advantage organizations (MAOs) "have the incentive to code intensely" and operate similar programs.

Strategic Takeaways for Insurance Professionals

For insurance carriers, this investigation illuminates both opportunity and risk. The sophisticated use of data analytics, AI, and integrated care delivery represents the competitive frontier in Medicare Advantage. Companies that can't match this operational sophistication will struggle to compete on risk adjustment accuracy.

For insurance agents marketing Medicare Advantage plans, understanding these backend operations becomes crucial for product positioning. Clients increasingly scrutinize whether their insurer's diagnosis documentation helps or hurts their medical record accuracy and continuity of care.

For digital marketers targeting senior health care audiences, the regulatory scrutiny creates both content opportunities and compliance considerations. Educational content about diagnosis accuracy, the difference between Medicare Advantage and traditional Medicare, and patient rights in documentation has never been more relevant.

What Comes Next

The Senate report makes no formal recommendations and stops short of accusing UnitedHealth of wrongdoing. However, Senator Grassley stated clearly: "Bloated federal spending to UnitedHealth Group is not only hurting the Medicare Advantage program, it's harming the American taxpayer."

Three key developments will shape the industry's trajectory:

Regulatory response—CMS is expected to release its 2027 Medicare Advantage rate notice in early 2026, which will signal whether regulators plan to tighten risk adjustment rules further. Any significant changes will force industry-wide operational adaptations.
DOJ resolution—The criminal investigation's outcome could result in charges, settlements, or both. Given Cigna's $172 million settlement precedent, any DOJ action would be material not just for UnitedHealth but as a deterrent signal to the entire industry.
Competitive dynamics—Smaller carriers without UnitedHealth's resources face a strategic choice: partner with UnitedHealth's systems, build competing capabilities, or accept lower risk adjustment accuracy. Each path carries distinct financial and regulatory implications.

Sources:

Becker's Hospital Review: Senate finds UnitedHealth used 'aggressive strategies' in Medicare Advantage
Fintool: News: Senate Report: UnitedHealth Used 'Aggressive Strategies' to Maximize Medicare Payments
Health Exec: Senate Report: UnitedHealth was aggressive in seeking higher Medicare Advantage payments
KFF Health News: UnitedHealth's Extreme Tactics Upped Medicare Payouts, Senate Inquiry Finds
The Hill: Grassley releases report accusing UnitedHealth of ‘gaming’ Medicare Advantage to boost diagnoses
U.S. Senate Committe on the Judiciary: How UnitedHealth Group Puts the Risk in Medicare Advantage Risk Adjustment
U.S. Senator Chuck Grassley: Grassley Report Details UnitedHealth’s Record of Appearing to Game the Medicare Advantage System, Turning Risk Adjustment into Its Own Business

Further Thoughts

This investigation exposes a fundamental tension in Medicare Advantage. The program was designed so insurers wouldn't avoid enrolling sicker patients by paying higher rates for members with documented chronic conditions. But when diagnosis capture itself becomes a profit center, the line between accurate documentation and gaming the system blurs.

For an industry built on actuarial precision and regulatory compliance, the Senate's findings demand serious reflection. The question isn't whether to optimize risk adjustment as every carrier must do so to compete. The question is how to optimize it within the spirit of the program's intent while maintaining both regulatory compliance and patient trust.

As the investigation continues and regulatory pressure mounts, one thing is certain: the Medicare Advantage market that emerges from this scrutiny will look different than the one that entered it. Insurance professionals who understand these dynamics, anticipate regulatory changes, and position their organizations accordingly will be best positioned to thrive in the evolving landscape.